Yusheng Liu

Yusheng Liu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in International Heart Journal
Verified
Journal Article
Open access
JHJiannan Huang
Jiannan Huang
YLYi Li
Yi Li
JZJuan Zhang
Juan Zhang
YLYusheng Liu
Yusheng Liu
QLQinghua Lu
Qinghua Lu
Hexarelin, a synthetic growth hormone-releasing peptide, has been proven to possess cardioprotective actions through its binding to the growth hormone secretagogue receptor (GHSR) 1a and the non-GHSR receptor CD36. However, its effect on myocardial ischemia/reperfusion (I/R) injury has not been fully clarified in vivo. We aimed to determine whether hexarelin treatment could protect cardiomyocytes from I/R injury and to examine the underlying mechanisms. In vivo hearts of male SD rats underwent 30 minutes of ischemia by left coronary artery ligation followed by reperfusion. The rats were then treated subcutaneously twice daily with hexarelin [100 μg/kg·day], ghrelin [400 μg/ kg·day], or saline for 7 days. Echocardiography, malondialdehyde detection, and histochemical staining were performed after treatment. In addition, Western blot was used to examine the expression levels of IL-1β, IL-1Ra, and IL-1RI. Our study showed that hexarelin treatment improved cardiac systolic function, decreased malondialdehyde production, and increased the number of surviving cardiomyocytes. The beneficial effects of hexarelin treatment were slightly superior to those of equimolar ghrelin treatment. We meanwhile confirmed that hexarelin induced down-regulation of IL-1β expression and up-regulation of IL-1Ra expression in I/R myocardium, which could be neutralized by the GHSR antagonist [D-Lys3]-growth hormone releasing peptide-6 ([D-Lys3]-GHRP-6). These findings suggest that hexarelin protects in vivo cardiomyocytes from I/R injury partly by modification of the IL-1 signaling pathway through the activation of cardiac GHSR1a receptors.

5 April 2022 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
WWWen-Ke Wang
Wen-Ke Wang
BWBen Wang
Ben Wang
XCXue-Hu Cao
Xue-Hu Cao
YLYusheng Liu
Yusheng Liu
Spironolactone improves cardiac structure, function and prognosis in patients with heart failure and delays the progression of cardiac fibrosis. However, the exact underlying mechanism of this process remains to be elucidated. The present study therefore aimed to explore the protective effect and underlying mechanism of the aldosterone receptor antagonist, spironolactone, on myocardial fibrosis in mice with experimental autoimmune myocarditis (EAM). The EAM model was induced in BALB/c mice via immunization with murine cardiac α‑myosin heavy chain sequence polypeptides. The cardiac function of the mice was assessed using echocardiography and the levels of inflammatory cytokines were quantified using ELISA. E26 transformation‑specific sequence‑1 (Ets‑1) expression was knocked down using lentivirus‑mediated small interference RNA. Total collagen deposition was assessed using Masson's trichrome and Ets‑1, TGF‑β1, Smad2/3, collagen I and III protein expression levels were detected using immunohistochemistry and western blotting. MMP‑2 and MMP‑9 mRNA expression levels and activity was determined using reverse transcription‑quantitative PCR and gelatin zymography, respectively. The results of the present study demonstrated that spironolactone significantly improved myocardium hypertrophy, diastolic cardiac function and decreased myocardial inflammation and collagen deposition induced by EAM. Spironolactone treatment significantly inhibited Ets‑1 and smad2/3 phosphorylation. In addition, inhibition of Ets‑1 reduced the expression and activity of MMP‑2 and MMP‑9 and decreased cardiac fibrosis in EAM mice. The results indicated that the improvement of myocardial fibrosis by spironolactone may be associated with the TGF‑β1/Smad‑2/3/Ets‑1 signaling pathway in EAM mice.

18 January 2025 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Open access
JKJiangying Kuang
Jiangying Kuang
ZJZhiyi Jia
Zhiyi Jia
TCTou Kun Chong
Tou Kun Chong
JCJian Chen
Jian Chen
KLKan Liu
Kan Liu
YLYusheng Liu
Yusheng Liu
Takotsubo syndrome (TTS) primarily manifests as a cardiomyopathy induced by physical or emotional stress, remains a poorly understood condition with no established treatments. In this study, we investigated the potential of sacubitril/valsartan (sac/val) to increase the survival of TTS patients and reduce inflammation and myocardial fibrosis in experimental models. This study aimed to evaluate whether sac/val could improve survival rates in TTS patients, mitigate cardiac remodeling in vivo, and explore its anti-inflammatory and antifibrotic mechanisms in vitro. Clinical cases from the Chinese Takotsubo syndrome (ChiTTS) registry were analyzed to assess patient survival rates. In addition, we used isoprenaline (ISO)-induced TTS-like animal models, pre-treated with sac/val, to evaluate cardiac function and inflammatory response. Additionally, the effects of isoprenaline on cardiomyocytes and myocardial fibroblasts, as well as protection from rhBNP, were thoroughly studied. In TTS patients with a left ventricular ejection fraction (LVEF) ≤ 0.45, hyperglycemia, emotional stress, and inflammation were identified as independent risk factors. Moreover, the baseline characteristics of the TTS patients, heart rate, emotional triggers, female sex (%), WBC count, IL-6 concentration, PCT, ALT, AST and TG were significantly associated with decreasing left ventricular ejection fraction. In TTS patients, sac/val reduced inflammation, evidenced by lower levels of white blood cells and interleukin 6, compared to patients who did not receive sac/val by day 30. In animal models, Sac/val improved cardiac dysfunction in ISO-induced TTS-like cardiomyopathy and decreased myocardial inflammatory responses (IL-18 and Mac-3) by inhibiting the TLR4/NF-κB pathway and fibrosis through the inhibition of the TGFβ1/Smad pathway. This study revealed that sac/val decreased inflammatory responses, myocardial edema, and fibrosis, resulting in an increased percentage of survivors in the TTS group. Similar to findings from in vivo and in vitro experiments, sac/val exerted cardioprotective effects by reducing the inflammatory response and reversing myocardial remodeling mediated by the TLR4/NF-κB and TGFβ1/Smad pathways. In conclusion, these findings highlight the anti-inflammatory and antifibrotic effects of sac/val in individuals with TTS.

21 January 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JKJiangying Kuang
Jiangying Kuang
KWKaiyi Wu
Kaiyi Wu
WLWenjing Li
Wenjing Li
XZXuguang Zhang
Xuguang Zhang
HZHao Zhang
Hao Zhang
YLYusheng Liu
Yusheng Liu
Background. Cardiac fibrosis (CF) is major myocardial change in diabetic cardiomyopathy (DCM). Yangxinshi as a Chinese medicine formula is used to treat cardiovascular diseases. However, the exact effective mechanism of Yangxinshi on CF is still uncertain. Hence, based on the pharmacological network, predicting the active components, potential targets and pathways of Yangxinshi on diabetic fibrosis require to be further studied. Materials and Methods. By using Cytoscape 3.6.0 Bisogenet plug-in, the active components of Yangxinshi were obtained and screened through TCMSP, and the PPI network of DCM-CF was constructed and then screened by CytoNCA plug-in. GO analysis and KEGG pathway enrichment analysis were carried out by Cluego plug-in. Combined with the results of network pharmacological analysis, cells in vitro were performed to verify the CF stimulated with high glucose or intervence with Yangxinshi, and the expressions of Cbl-b, p-smad2, and α-SMA were detected. Results. Yangxinshi might play a key role in reversing cardiac fibrosis in individuals with DCM by regulating the signal pathway of CBL and promoted the expression of Cbl-b and inhibited the expression of p-smad2 and α-SMA, verifying some predictive work via network pharmacology. Conclusion. Based on network pharmacology, this study demonstrates that the beneficial effect of Yangxinshi on CF is related to the Cbl-b/smad2 pathway, providing an idea for the therapeutic effect of Yangxinshi on cardiac fibrosis in DCM.

17 April 2026 in PLOS ONE
Verified
Journal Article
Open access
XTXiaochen Tian
Xiaochen Tian
JLJing Li
Jing Li
THTao Han
Tao Han
LZLeisheng Zhang
Leisheng Zhang
PLPing Lu
Ping Lu
YLYusheng Liu
Yusheng Liu
Diabetic nephropathy (DN) is a major diabetic complication, and while DJ-1 has been shown to mitigate renal ischemia/reperfusion injury, its role in high glucose-induced podocyte damage remains unclear. This study aimed to investigate the function and mechanism of DJ-1 in high glucose-induced injury of human podocyte cells (HPCs). Using RNA-seq analysis, we identified that high glucose broadly affected multiple signaling pathways related to cell growth, death, and signal transduction. Notably, DJ-1 expression was downregulated under high glucose conditions. Overexpression of DJ-1 significantly attenuated high glucose-induced HPC apoptosis. Mechanistically, DJ-1 promoted the phosphorylation of ERK1/2 and facilitated the nuclear translocation of p-ERK1/2. This activated the ERK1/2 pathway and upregulated the expression of NF-κB p65 and AP-1, thereby suppressing HPC apoptosis under high glucose conditions. In summary, our findings reveal that DJ-1 protects against high glucose-induced HPC injury by activating the ERK1/2 pathway and enhancing NF-κB p65 and AP-1 expression, providing new insights into the molecular mechanisms of DJ-1 in diabetic nephropathy.

6 October 2026 in Phytotherapy Research
Verified
Journal Article
Open access
PDF file
ZJZhiyi Jia
Zhiyi Jia
KWKaiyi Wu
Kaiyi Wu
JQJiaying Qi
Jiaying Qi
NHNana Huang
Nana Huang
YLYusheng Liu
Yusheng Liu
RSRong Sun
Rong Sun
Metabolic syndrome (MetS) represents a clinical disorder characterized by the clustering of conditions including obesity, elevated blood sugar levels, and high lipid levels, which are intricately linked to the onset of cardiovascular diseases (CVDs), such as atherosclerosis, myocardial ischemia‐reperfusion injury (MIRI), and heart failure (HF). Salvia miltiorrhiza Bunge (SM), recognized as a blood‐regulating herb in traditional Chinese medicine (TCM), is renowned for its effects in activating blood and resolving stasis. By summarizing the pharmacological research progress and clinical efficacy of SM and its active components in the management of MetS and CVDs, this review analyzes its multi‐dimensional pharmacological characteristics and multi‐target action pathways, and identifies common pharmacological effects and target networks. Through a comprehensive computational integration of network pharmacology, bioinformatics analyses, ADMET profiling, PASS online bioactivity prediction, and molecular docking, candidate targets and shared signaling pathways underlying the therapeutic potential of SM in MetS and CVDs were explored. These findings were then interpreted in the context of an integrated appraisal of clinical evidence for various SM preparations in managing MetS and CVDs, together with a thorough examination of pharmacological data on SM and its major bioactive compounds. The reviewed clinical and experimental evidence indicates that SM‐containing formulations and major SM constituents may modulate several pathophysiological mechanisms shared by MetS and CVDs, particularly inflammation, metabolic dysregulation, oxidative stress, and tissue remodeling. The exploratory computational integration further prioritized PIK3CG, IKBKB, JAK2, STAT3, and IL1B as candidate shared targets associated with NF‐κB, PI3K/Akt, MAPK, and AGE/RAGE signaling. SM and its active components have shown potential multi‐target, multi‐pathway, and multi‐action effects in MetS and CVDs, providing preliminary evidence for the treatment principle of “same treatment for different diseases.”